Eledon Pharmaceuticals
Eledon Pharmaceuticals
ELDN
NASDAQ
3.80
USD
2.98%
About
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway.
The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages.
CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 55.1K |
| Three Month Average Volume | 2.3M |
| High Low | |
| Fifty-Two Week High | 3.349 USD |
| Fifty-Two Week Low | 1.07 USD |
| Fifty-Two Week High Date | 20 May 2024 |
| Fifty-Two Week Low Date | 09 Nov 2023 |
| Price and Volume | |
| Current Price | 2.81 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -3.63% |
| Thirteen Week Relative Price Change | -4.53% |
| Twenty-Six Week Relative Price Change | 58.73% |
| Fifty-Two Week Relative Price Change | 47.53% |
| Year-to-Date Relative Price Change | 31.83% |
| Price Change | |
| One Day Price Change | -1.40% |
| Thirteen Week Price Change | 2.18% |
| Twenty-Six Week Price Change | 74.53% |
| Five Day Price Change | -3.10% |
| Fifty-Two Week Price Change | 84.87% |
| Year-to-Date Price Change | 56.11% |
| Month-to-Date Price Change | -4.42% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 3.4452 USD |
| Book Value Per Share (Most Recent Quarter) | -0.22077 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.10766 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -1.06182 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.41842 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.63799 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.51588 USD |
| Normalized (Last Fiscal Year) | -1.63799 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.63799 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.51588 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.63799 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.51588 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.11051 USD |
| Cash Per Share (Most Recent Quarter) | 2.17132 USD |
| Cash Flow Per Share (Last Fiscal Year) | -99999.99 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -99999.99 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.14597 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -34.08% |
| Tangible Book Value (5 Year) | 32.23% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 61.22% |
| EPS Change (Trailing Twelve Months) | 69.75% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -83,610,000 |
| Net Debt (Last Fiscal Year) | -51,102,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 14 |
| Current Ratio (Most Recent Quarter) | 14 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -39,527,000 |
| Free Cash Flow (Trailing Twelve Months) | -37,897,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -44.35% |
| Return on Assets (Trailing Twelve Months) | -77.89% |
| Return on Assets (5 Year) | -38.44% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -48.12% |
| Return on Equity (Trailing Twelve Months) | -193.58% |
| Return on Equity (5 Year) | -40.55% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -47.03% |
| Return on Investment (Trailing Twelve Months) | -81.83% |
| Return on Investment (5 Year) | -39.80% |